



The 15th World Congress on  
**Controversies in Obstetrics,  
Gynecology & Infertility (COGI)**  
*All about Women's Health*

**Hainan, China, December 8-11, 2011**

## CONGRESS PROGRAM



A comprehensive Congress fully devoted to clinical **Controversies, debates and consensus** on a wide spectrum of topics in **Obstetrics, Gynecology and Infertility**

**[www.congressmed.com/cogichina](http://www.congressmed.com/cogichina)**  
**[cogichina@congressmed.com](mailto:cogichina@congressmed.com)**

# TIMETABLE

Thursday, December 8, 2011	
19:00-20:30	Welcome reception - Cocktail

Friday, December 9, 2011				
	Infertility & ART Hall A	Gynecology Hall B	Fetomaternal Hall C	Free Communications Hall D
08:30-10:00	PLENARY OPENING SESSION			
10:00-10:20	Coffee break			
10:20-11:50	MILD STIMULATION FOR IVF	HRT: WHERE ARE WE HEADING?	INCREASING CAESAREAN SECTION RATE: HOW MUCH IS TOO MUCH?	INFERTILITY
11:50-12:10	Posters viewing			
12:10-13:40	PREIMPLANTATION GENETIC SCREENING (PGS): WHAT IS NEXT? <i>Supported by unrestricted grant from IBSA</i>	POSTMENOPAUSAL OSTEOPOROSIS	CONTROVERSIES IN PRETERM LABOR AND DELIVERY	FETOMATERNAL MEDICINE
13:40-14:30	Lunch break			
14:30-16:00	IN VITRO MATURATION (IVM) <i>Supported by unrestricted grant from IBSA</i>	WOMEN AND OVARIAN CANCER: FROM CONCEPTION TO DIAGNOSIS	GESTATIONAL DIABETES MELLITUS (GDM)	GYNECOLOGY
16:00-16:30	Coffee break			
16:30-18:00	IMPROVING RESULTS IN IVF	FAMILY PLANNING	PRENATAL DIAGNOSIS	INFERTILITY

Saturday, December 10, 2011				
	Infertility & ART Hall A	Gynecology Hall B	Fetomaternal Hall C	Free Communications Hall D
08:30-10:00	ASSESSMENT AND TREATMENT OF OVARIAN RESERVE	COSMETIC GENITAL SURGERY	COMPLICATIONS OF PREGNANCY AND DELIVERY	INFERTILITY
10:00-10:20	Coffee break			
10:20-11:50	POLYCYSTIC OVARIAN SYNDROME (PCOS) AND OHSS	CONTROVERSIES IN THE TREATMENT OF MALIGNANCIES	CERCLAGE	FETOMATERNAL MEDICINE
11:50-12:10	Posters viewing			
12:10-13:40	HOT CONTROVERSIES ON ART CLINICAL ISSUES	ENDOSCOPY <i>Supported by unrestricted grant from Karl Storz GMBA</i>	MULTIPLE PREGNANCIES	FETOMATERNAL MEDICINE/GYNECOLOGY
13:40-14:30	Lunch break			
14:30-16:00	BASIC LABORATORY ASPECTS OF ART	OPERATIVE PROCEDURES: TRICKS OF THE TRADE	HIGH RISK PREGNANCIES IN ART: A PRICE TO PAY <i>(Bilateral encounter of Primatologists and Infertility Specialists)</i>	FETOMATERNAL MEDICINE/GYNECOLOGY
16:00-16:30	Coffee break			
16:30-18:00	ONCOFERTILITY: THE PRESERVATION OF FUTURE GENERATIONS	CERVICAL CANCER AND HUMAN PAPILOMA VIRUS (HPV)	COMPLICATIONS OF PREGNANCY (II)	

Sunday, December 11, 2011		
	Infertility & ART Hall A	Hall B
08:30-10:00	RESCUE ICSI, SHOULD WE KEEP DOING IT?	HORMONE THERAPY (HT) AND CANCER RISK
10:00-10:30	Coffee break	
10:30-12:30	ENDOMETRIOSIS: WHAT IS THE BEST TREATMENT FOR INFERTILE PATIENTS?	SPECIAL SESSION OF THE RUSSIAN SOCIETY OF OB/GYN IN CONJUNCTION WITH COGI CHINA

## THURSDAY, DECEMBER 8, 2011

19:00-20:30 Welcome Reception - Cocktails

## FRIDAY, DECEMBER 9, 2011

<b>08:30-10:00</b> Chairpersons	<b>OPENING SESSION</b> <b>J.H. Lang</b> , China (Honorary Chairman) <b>C.Q. Zhou</b> , China <b>G. Lu</b> , China <b>Z.J. Chen</b> , China <b>Z. Ben Rafael</b> , Israel
<b>08:30-08:35</b>	<b>Opening remarks</b> Experts views on where our field is heading
08:35-08:55	Stem cells and their significance in gynecology <b>C. De Geyter</b> , Switzerland
08:55-09:15	Sperm fitness testing and experimental IVF on integrated Lab-on-a-Chip devices <b>J. Cheng, K. Mitchelson</b> , China
09:15-10:00	When will laparoscopy replace almost all laparotomies? <b>C.R. Nezhat</b> , USA
Capsule	<i>Video-Laparoscopy is developing fast, covering an ever growing number of operations and disciplines Prof. Nezhat, often referred to as a "Wizard" in Laparoscopy, will present his personal view, an odyssey of science technology and will explain where Video-Laparoscopy is heading and if this technology will ever put to rest all laparotomies, and in his words: "The objectives of the lecture are, to motivate the younger physicians, bring hope to their work and education and encouragement in their careers"</i>
<b>10:00-10:20</b>	<b>Coffee break</b>

### INFERTILITY AND ART

### HALL A

<b>10:20-11:50</b> Capsule	<b>MILD STIMULATION FOR IVF</b> <i>Proponents of monofollicular stimulation claim that this is the way for IVF, especially in an era of single embryo transfer (SET). Opponents, in turn, suggest that pregnancy rates are too low to make it a viable alternative. Can we agree on what direction we should take?</i>
Chairpersons	<b>S.A. Carson</b> , USA <b>Z.J. Chen</b> , China
10:20-11:05	Debate <b>Should We Always Strive to Use Mild Stimulation for IVF?</b> <b>Proposition:</b> Mild stimulation IVF combined with single embryo transfer (SET) should be the method used for IVF <b>S. Daya</b> , Canada <b>Opposition:</b> Results are too low and dropout rates are too high to make it a viable option! <b>N. Gleicher</b> , USA Discussion
11:05-11:50	Debate <b>Preventing all Multiple Pregnancies by Systematic Single Embryo Transfer (SET) for all?</b> <b>Yes:</b> <b>G.N. Huang</b> , China <b>No:</b> <b>N. Gleicher</b> , USA Discussion
Objectives	<i>To acquire knowledge about the following:</i> <ul style="list-style-type: none"> <li>• What is "mild" stimulation and what are its advantages and disadvantages</li> <li>• Which patients are the most likely candidates for such stimulation</li> <li>• Arguments for and against SET</li> <li>• SET utilization in different parts of the world and related government regulations</li> <li>• Why transfer of more than one embryo remains popular amongst patients and physicians</li> </ul>

<b>11:50-12:10</b>	<b>Poster viewing</b>
<b>12:10-13:40</b>	<b>PREIMPLANTATION GENETIC SCREENING (PGS): WHAT IS NEXT?</b> <i>Supported by unrestricted grant from IBSA</i>
Capsule	<i>Preimplantation genetic diagnosis (PGD) was initially introduced to identify single gene defects, but evolved under the acronym "PGS" (preimplantation genetic screening) into a tool to detect embryo aneuploidy. The proposed goal was to improve pregnancy rates in IVF, and reduce spontaneous abortion rates. Thus far, studies indicate that in order to compensate for the risks involved, improvement of more than 10% is needed. The current question is does the future of PGS lie in the technical improvements? Can we keep refining the method, using newer technologies such as comparative genomic hybridization (CGH), and embryo diagnosis via trophectoderm biopsy?</i>
Chairpersons	<b>S. Daya</b> , Canada <b>M. von Wolff</b> , Switzerland <b>C. De Geyter</b> , Switzerland
12:10-12:55	<p>Debate</p> <p><b>PGS is an Experimental Tool that Should be Banned from Routine Clinical Use!</b></p> <p><b>Proposition:</b> PGS, as currently practiced, is associated with inferior results and should not be routinely offered <b>N. Gleicher</b>, USA</p> <p><b>Opposition:</b> The beneficial effects of preimplantation genetic diagnosis for aneuploidy support extensive clinical applications <b>G.X. Lu</b>, China</p>
12:55-13:15	Can CGH in PGS be the answer for the inefficiencies in PGS? <b>K.W.R. Choy</b> , Hong Kong
13:15-13:40	Meiotic contribution to aneuploidy <b>Y.W. Xu</b> , China
Objectives	<i>Upon completion of this debate, the audience will learn:</i> <ul style="list-style-type: none"> <li>• <i>The hypothesis that makes PGS an attractive proposition</i></li> <li>• <i>Reasons why PGS, as performed, failed to meet expectations</i></li> <li>• <i>New technologies and techniques, which potentially, may positively affect PGS results</i></li> <li>• <i>What the IVF field can learn from the PGS experience</i></li> <li>• <i>About CGH and its role in future PGS</i></li> </ul>
<b>13:40-14:30</b>	<b>Lunch break</b>

<b>14:30-16:00</b>	<b>IN VITRO MATURATION (IVM)</b> <i>Supported by unrestricted grant from IBSA</i>
Capsule	<i>IVM is becoming more effective, but will it ever replace IVF? Benefits, risks and pitfalls of the procedure</i>
Chairpersons	<b>C. De Geyter</b> , Switzerland <b>H.F. Huang</b> , China
14:30-15:15	<p>Debate</p> <p><b>Will IVM Ever Replace Standard IVF?</b></p> <p><b>Yes:</b> Results of IVM are comparable to standard IVF with or without stimulation <b>M. Benkhalifa</b>, France</p> <p><b>No:</b> IVM does not offer any advantage over current IVF practice <b>X. Liang</b>, China</p> <p>Discussion</p>
15:15-15:40	IVM for PCOS patients <b>M. Benkhalifa</b> , France
15:40-16:00	What have we learned from oocyte donation programs! <b>O. Coll</b> , Spain
Objectives	<i>Upon completion of this session, the audience will have acquired:</i> <ul style="list-style-type: none"> <li>• <i>Understanding of the place of IVM in comparison to IVF</i></li> <li>• <i>Understanding of the laboratory procedures</i></li> <li>• <i>Special indications for IVM</i></li> <li>• <i>IVM for PCOS</i></li> <li>• <i>PCOS as egg donors</i></li> </ul>
<b>16:00-16:30</b>	<b>Coffee break</b>
<b>16:30-18:00</b>	<b>IMPROVING RESULTS IN IVF</b>
Capsule	<i>Improving the results of IVF requires that each aspect of the treatment from the clinical elements of ovarian stimulation, to laboratory work and quality assurance, to awareness of infection and risk, and embryo transfer techniques be boosted. Disagreement exists over basic procedures and also over the universal use of ICS</i>
Chairpersons	<b>O. Coll</b> , Spain <b>C.Q. Zhou</b> , China <b>Z.J. Chen</b> , China
16:30-16:55	Quality Management in IVF <b>B. Imthurn</b> , Switzerland
16:55-17:15	The standardization and safety of ART <b>G.X. Lu</b> , China
17:15-17:40	Impact of viral infection on reproductive function <b>O. Coll</b> , Spain
17:40-18:00	Is ICSI overused? <b>J. Liu</b> , China
Objectives:	<i>Upon completion of this session, the audience will have learned:</i> <ul style="list-style-type: none"> <li>• <i>QA and QC in the lab work</i></li> <li>• <i>Effect of infection on the results</i></li> <li>• <i>Are we abusing ICSI?</i></li> </ul>

<b>10:20-11:50</b> Capsule	<p><b>HRT: WHERE ARE WE HEADING?</b></p> <p><i>WHI has brought about a sharp decline in hormone replacement therapy (HRT/HT) in asymptomatic and symptomatic women. A key criticism of WHI is the age of the population selected, which is well above the critical age window where HT is still expected to prevent (if at all) cardiovascular disease (CVD) Whether all (class effect) or only certain type of progesterone are to be blamed and whether estrogens are really carcinogenic is another controversial aspect of this discussion.</i></p>
Chairpersons	<p><b>R. Langer</b>, USA  <b>E. Peer</b>, Israel  <b>Y. Qi</b>, China</p>
10:20-11:05	<p>Debate</p> <p><b>Is There Evidence for a HT Critical Window to Prevent Disease?</b></p> <p>Proposition: HRT should be started early to have an effect</p> <p><b>R. Langer</b>, USA</p> <p>Opposition: No evidence exists for the "critical window" theory</p> <p><b>S. Skouby</b>, Denmark</p> <p>Discussion</p>
11:05-11:30	<p>The hormonal connection to breast cancer from molecular biology to clinical implications. Are all progesterones the same?</p> <p><b>E. Peer</b>, Israel</p>
11:30-11:50	<p>The WHO defines estrogens as "Carcinogenic": Fact or fallacy?</p> <p><b>A. Mueck</b>, Germany</p>
Objectives	<p><i>Upon completion of this session, the audience will learn:</i></p> <ul style="list-style-type: none"> <li>• <i>Whether it is still customary to prescribe HT, and to whom</i></li> <li>• <i>If HT is "a must" in premature menopause</i></li> <li>• <i>The place of androgens in HT</i></li> </ul>
<b>11:50-12:10</b>	<b>Poster viewing</b>
<b>12:10-13:40</b> Capsule	<p><b>POSTMENOPAUSAL OSTEOPOROSIS</b></p> <p><i>The usual patients with low bone mineral density and fracture risk who are seen by a gynecologist are often younger than 70 years, while research on drugs is undertaken on women over this age</i></p>
Chairpersons	<p><b>A. Mueck</b>, Germany  <b>X. Ruan</b>, China  <b>Y. Qi</b>, China</p>
12:10-13:15	<p>Debate</p> <p><b>Should we Treat Women with Low Bone Mineral Density Who are Younger than 70 Years, and How?</b></p> <p><b>Proposition:</b> Evidence for the effectiveness of drugs at this age is lacking, and treatment is not cost-effective</p> <p><b>R. Langer</b>, USA</p> <p><b>Opposition:</b> There is enough experience to manage these patients, but therapy should be individualized</p> <p><b>S. Skouby</b>, Denmark</p> <p>Discussion</p>
13:15-13:40	<p>Denosumab, the horizon for future treatment of osteoporosis: Rank-L story</p> <p><b>E. Peer</b>, Israel</p>
Objectives	<p><i>To acquire knowledge of the following:</i></p> <ul style="list-style-type: none"> <li>• <i>Risk factors and prevalence of osteoporotic fractures in women over 70 years</i></li> <li>• <i>FRAX index in this age group, DEXA indication</i></li> <li>• <i>Older and newer methods to prevent fractures</i></li> </ul>
<b>13:40-14:30</b>	<b>Lunch break</b>

<b>14:30-16:00</b>	<b>WOMEN AND OVARIAN CANCER: FROM CONCEPTION TO DIAGNOSIS</b>
Capsule	<i>Early diagnosis of ovarian cancer can improve prognosis!</i>
Chairpersons	<b>R. Moore</b> , USA <b>T. Levy</b> , Israel
14:30-15:00	Ovarian cancer screening <b>T. Levy</b> , Israel
15:00-15:30	Pelvic mass risk assessment: Who is at high risk for ovarian cancer? <b>R. Moore</b> , USA
15:30-16:00	Pelvic mass in pregnancy: When do we need to intervene? <b>C.O. Granai</b> , USA
Objectives	<i>To acquire knowledge of the following:</i> <ul style="list-style-type: none"> <li>• <i>Screening strategies for women at high risk for ovarian cancer</i></li> <li>• <i>When pelvic mass is suspected to be cancer</i></li> <li>• <i>Treatment of pelvic mass during pregnancy</i></li> </ul>
<b>16:00-16:30</b>	<b>Coffee break</b>
<b>16:30-18:00</b>	<b>FAMILY PLANNING</b>
Capsule	<i>The field of family planning is constantly evolving in an effort to provide the right solution to most women and situations with minimal risks. What are the risks and how can we minimize them?</i>
Chairpersons	<b>E. Peer</b> , Israel <b>S. Skouby</b> , Denmark
16:30-16:55	Hormonal contraception: Obesity and diabetes <b>S. Skouby</b> , Denmark
16:55-17:15	Advantages of medicated IUD over non medicated in nulliparous women <b>A. Ber</b> , Israel
17:15-17:40	Efficacy of LNG as an emergency contraceptive: A phase 4 trial <b>L.N. Cheng</b> , China
17:40-18:00	LARC (long acting reversible contraception): An update <b>S. Skouby</b> , Denmark
Objectives	<i>To acquire knowledge of the following:</i> <ul style="list-style-type: none"> <li>• <i>Risk of OC's</i></li> <li>• <i>IUS to nulliparous</i></li> <li>• <i>Emergency Contraception</i></li> <li>• <i>LARC</i></li> </ul>

<b>10:20-11:50</b> Capsule	<b>INCREASING CAESAREAN SECTION RATE: HOW MUCH IS TOO MUCH?</b> <i>One of the hottest controversies is the huge increase in CS rates worldwide. Viewed by some as a blessing and a modern response to obstetrics needs, others view it as a lack of discipline and understanding</i>
Chairpersons	<b>W.H. Tam</b> , Hong Kong <b>H. Divakar</b> , India
10:20-11:20	<b>Hot Topic: Increasing rates of CS the right way to go?</b> Is there a midway between the view that "CS for all should be the target" and the view that "Understanding overall Caesarean section rates will help limit the rising rates" <b>M. Robson</b> , Ireland Discussion
11:20-11:50	LMWH for pregnancy loss: To treat or not to treat? <b>I. Blickstein</b> , Israel
Objectives:	<i>To acquire knowledge on the following:</i> • <i>The reasons, and pros and cons of the sharp increase in CS rates</i> • <i>Prevention of VTE</i>
<b>11:50-12:10</b>	<b>Poster viewing</b>
<b>12:10-13:40</b> Capsule	<b>CONTROVERSIES IN PRETERM LABOR AND DELIVERY</b> <i>Despite the high fetal morbidity and mortality that is associated with premature delivery, there is currently neither a tool specific enough to diagnose premature labor, nor a good intervention available to effectively interrupt the vicious circle of labor.</i>
Chairpersons	<b>W.H. Tam</b> , Hong Kong <b>W. Holzgreve</b> , Switzerland
12:10-12:40	Diagnosis of preterm labor (PTL) and prediction of premature delivery (PMD): Who to treat, and who not to treat? <b>I. Blickstein</b> , Israel
12:40-13:10	Why do we use tocolysis at all? <b>M. Robson</b> , Ireland
13:10-13:40	Should we repeat atosiban tocolysis as frequently as required? <b>I. Blickstein</b> , Israel
Objectives	<i>Upon completion of this session, the audience will have learned:</i> • <i>The pitfalls of diagnosis and treatment of PTL</i> • <i>Selecting who to treat</i> • <i>The place of tocolysis in PTL</i>
<b>13:40-14:30</b>	<b>Lunch break</b>



**14:30-16:00 GESTATIONAL DIABETES MELLITUS (GDM)**

**Capsule** *The association of milder forms of GDM with perinatal morbidity and mortality remains unclear, primarily because the condition is often confounded with other risk factors, such as maternal obesity, age, and parity which increase the risks of adverse pregnancy outcomes. The implementation of the HAPO results into recommendations increases the number of patients labeled to have GDM from 4% to 16%. While many would welcome the doubling of patients' load the question is, will increased expenditure improve the outcome?*

**Chairpersons** **I. Blickstein**, Israel  
**W. Holzgreve**, Switzerland

14:30-15:15 The pros and cons surrounding the implementation of HAPO study recommendations: Will it increase the safety of pregnancy or just increase the number of patients labeled as GDM  
**W.H. Tam**, Hong Kong

**Discussant** **W.H. Tam**, Hong Kong

15:15-15:30 **Questions**  
1. Should women with obesity and DM try to lose weight while pregnant?  
2. Long term effects of GDM on neonate, fetal origin of maternal diseases

15:30-16:00 Active Management of Labor: What is the evidence?  
**M. Robson**, Ireland

**Objectives** *To acquire knowledge on the following: The disadvantages of HAPO study implementation*  
• Long term effects and complications of GDM  
• Risks of obesity in GDM  
• The role of active management of labor in current obstetrics

**16:00-16:30 Coffee break**

**16:30-18:00 PRENATAL DIAGNOSIS**

**Capsule** *Prenatal diagnosis is evolving fast, and soon we'll be able to get a full noninvasive screening*

**Chairpersons** **T.Y. Leung**, Hong Kong  
**W. Holzgreve**, Switzerland

16:30-16:50 Non-invasive prenatal diagnosis from maternal blood: Finally available in clinical practice after 20 years of research  
**W. Holzgreve**, Switzerland

16:50-17:15 Is there any role of NT and biochemical screening in the era of non-invasive prenatal diagnosis?  
**T.Y. Leung**, Hong Kong

17:15-17:40 Evaluation of the cervix with new wireless device  
**W. Holzgreve**, Switzerland

17:40-18:00 Comparative genomic hybridization-array analysis enhances the detection of aneuploidies and submicroscopic imbalances in spontaneous miscarriages  
**K.W.R. Choy**, Hong Kong

**Objectives** *To acquire knowledge on the following:*  
• Different prenatal noninvasive diagnostic methods and their limitation  
• The place of CGH

**18:30-19:45**

**Special entertaining performance of  
"Snakes, Bugs and Us"  
By C.O. ("Skip") Granai, MD, USA  
Please invite your spouse**

**10:20-11:50 ORAL SESSION 1: INFERTILITY**

- Chairperson **M. Benkhalifa, France**
- 10:20-10:30 **STUDY OF GTN-REPEAT EXPANSION IN HEME OXYGENASE-1 GENE PROMOTER AS GENETIC CAUSE OF MALE INFERTILITY**  
E. Siasi, *Islamic Republic of Iran*
- 10:30-10:40 **MARS-MALE REPRODUCTIVE SURGERY AND MICROSURGERY**  
G. Tritto, *Hungary*
- 10:40-10:50 **PPARY AND KI-67 EXPRESSION IN TROPHOBLASTIC CELLS IN WOMEN WITH MISSED ABORTION AFTER ASSISTED REPRODUCTIVE TECHNOLOGY**  
N. Aleksandrova, E. Dubova, O. Baev, A. Shchegolev, G. Sukhikh, *Russian Federation*
- 10:50-11:00 **SPERM BANKING AND ASSISTED REPRODUCTION TREATMENTS USING CRYOPRESERVED SPERM FROM CANCER PATIENTS: EXPERIENCE OF A SINGLE TERTIARY INFERTILITY CENTER**  
A. Botchan, *Israel*
- 11:00-11:10 **ROLE OF LUTEAL PHASE ADMINISTRATION OF LOW MOLECULAR WEIGHT HEPARIN IN IVF-ICSI EMBRYO REPLACEMENT CYCLES TO IMPROVE IMPLANTATION**  
S. Sridev, T. Varma, *India*
- 11:10-11:20 **HUMAN BLASTOCYST CRYOPRESERVATION: VITRIFICATION HAD BETTER SURVIVAL RATE AND FAST RECOVERY SPEED, BUT PREGNANCY OUT COME WAS SIMILAR COMPARED TO SLOW-FREEZING METHOD**  
J. Ding, N. Rana, E. Truckhacheva, W.P. Dmowski, *USA*
- 11:20-11:30 **THE RELATIONSHIP BETWEEN HEAVY METAL EXPOSURE AND RISK OF INFERTILITY IN TAIWANESE WOMEN**  
H-Y. Ho, W. Hsiao-Jui, R. Young, Y. San-Li, K. I-Li, *Chinese Taipei*
- 11:30-11:40 **ROLE OF CABERGOLINE, DOPAMINE AGONIST IN PREVENTION OF OHSS AND ITS EFFECT ON PREGNANCY OUTCOME**  
S. Prabhakar, *India*
- 11:40-11:50 **STRESSORS IMPEDING OVULATION IN MAMMALS – EXPERIENCE IN DAIRY CATTLE AND BUFFALOES**  
M. Qureshi, *Pakistan*

**12:10-13:40 ORAL SESSION 2: FETOMATERNAL MEDICINE**


- Chairperson **H. Divakar, India**
- 12:10-12:20 **USE OF UTERINE ELECTROMYOGRAPHY TO DIAGNOSE TERM AND PRETERM LABOR**  
S. Shi, R. Garfield, L. Shi, *USA*
- 12:20-12:30 **PSYCHOLOGICAL TRAUMA IN CHILDBIRTH AND MOTHER'S REACTION: A QUALITATIVE APPROACH**  
Z. Taghizadeh, M. Arbabi, A. Irajpoor, S. Nejat, A. Kazemnejad, *Islamic Republic of Iran*
- 12:30-12:40 **IMMEDIATE CESAREAN DELIVERY IN PREGNANCIES COMPLICATED WITH SEVERE PRECLAMPSIA**  
S. Sarsam, *Iraq*
- 12:40-12:50 **INCREASE IN MALE FETAL DEATHS IN JAPAN AND CONGENITAL ANOMALIES OF THE KIDNEY AND URINARY TRACT**  
R. Mizuno, *Japan*
- 12:50-13:00 **CARDIAC ARREST IN A PATIENT WITH PREECLAMPSIA AND HISTORY OF PERIPARTUM CARDIOMYOPATHY**  
K. Chaudhuri, J. Meyers, A. Olufulabi, M. Swaminathan, *USA*
- 13:00-13:10 **THE STUDY AND COMPARISON OF AGE CONDITIONS IN MARRIAGE AND FIRST PREGNANCY IN PREGNANT WOMEN ATTENDING HEALTH CENTERS OF MASHHAD AND BOJNORD, IRAN 2010**  
M. Ghabel, T. Khadivzade, M. Khadem Ahmatabadi, *Islamic Republic of Iran*
- 13:10-13:20 **THE SURVEY OF GHRELIN CONCENTRATION IN SERUM AND CORD BLOOD AND ITS CORRELATION WITH INFANT GROWTH PARAMETERS**  
H. Hadinedoushan, *Islamic Republic of Iran*
- 13:20-13:30 **THE EFFECT OF BREAST FEEDING TRAINING PROGRAM ON THE KIND OF NUTRITION AND GROWTH INDEX PRETERM NEWBORN**  
M. Gholamitabar Tabari, *Islamic Republic of Iran*
- 13:30-13:40 **PLACENTAL SPECIFIC MICRORNAS IN MATERNAL CIRCULATION AND THEIR DIAGNOSTICAL POTENTIAL FOR PLACENTAL INSUFFICIENCY RELATED COMPLICATIONS**  
I. Hromadnikova, K. Kotlabova, J. Doucha, K. Dlouha, *Czech Republic*

**14:30-15:40 ORAL SESSION 3: GYNECOLOGY**

- Chairperson **T. Levy, Israel**
- 14:30-14:40 **FEMALE GENITAL MUTILATION/CUTTING: AN UPDATE**  
**A. Rouzi, Saudi Arabia**
- 14:40-14:50 **ULTRASOUND-GUIDED TRANSLUMINAL RADIOFREQUENCY ABLATION OF ADENOMYOSIS: AN 8 YEAR EXPERIENCE**  
**J-H. Nam, Republic of Korea**
- 14:50-15:00 **EXPANDING ACCESS TO EMERGENCY CONTRACEPTION UNDER THE SCOTTISH SEXUAL HEALTH STRATEGY: CAN RATES OF UNINTENDED PREGNANCY BE REDUCED?**  
**J. McGowan, United Kingdom**
- 15:00-15:10 **MYOMECTOMY: MINI-INVASIVE APPROACH**  
**O. Shalaev, L. Salimova, N. Plaksina, F. Eseneeva, T. Ignatenko, Russian Federation**
- 15:10-15:20 **THE COMBINED CONTRACEPTIVE RING, NUVARING, VERSUS AN ORAL CONTRACEPTIVE CONTAINING 30 MG ETHINYL ESTRADIOL AND 3 MG DROSPIRENONE**  
**A. Maged, W. Mostafa, W. Sherbiny, Egypt**
- 15:20-15:30 **ACCESSORY BREAST CANCER – DIFFICULTIES IN DIAGNOSIS AND THERAPY**  
**B. Madej-Czerwonka, M. Czerwonka, Poland**
- 15:30-15:40 **ASSOCIATION OF HPV WITH DIFFERENT KNOWN RISK FACTORS FOR NEOPLASTIC CERVICAL LESIONS**  
**M.H. Bukhari, K. Saba, M. Zainab, G. Ahmad, I. Qaderi, Pakistan**

**16:30-18:00 ORAL SESSION 4: INFERTILITY**

- Chairperson **O.Coll, Spain**
- 16:30-16:40 **UTERINE SEPTUM DISSECTION USING SMALL-DIAMETER HYSTEROSCOPY WITH BIPOTRODE 5 FR BIPOLAR ELECTRODE VERSUS MONOPOLAR RESECTOSCOPY WITH A UNIPOLAR KNIFE: A PROSPECTIVE RANDOMIZED STUDY**  
**H. Youssef, Egypt**
- 16:40-16:50 **THE CLINICAL OUTCOMES OF INFERTILE WOMEN WITH PCOS UNDERGOING IN-VITRO MATURATION TREATMENT**  
**B. Ye, J-Z. Zhao, P-Y. Wang, China**
- 16:50-17:00 **EFFECTS OF EXOGENOUS LUTEINIZING HORMONE ON PATIENTS WITH RELATIVE LH DEFICIENCY AFTER PITUITARY DOWN-REGULATION DURING CONTROLLED OVARIAN HYPERSTIMULATION**  
**Z. Niu, Y. Feng, Q. Chen, Y. Sun, L. Xiaowei, Z. Aijun, China**
- 17:00-17:10 **THE SPERM PARAMETERS AND COUPLES AGES AS PREDICTIVE FACTORS FOR SUCCESSFUL INTRAUTERINE INSEMINATION**  
**A. Daliri Hampa, M. Sabbaghian, H. Hoseinifar, T. Modarresi, R. Nakhjavani, S.J. Hoseini, M.A. Sadighi Gilani, Islamic Republic of Iran**
- 17:10-17:20 **PREGNANT SITUATION AND NEONATAL OUTCOMES AFTER VITRIFIED EMBRYO TRANSFERS: A PRELIMINARY STUDY**  
**X. Wang, China**
- 17:20-17:30 **THE EXPRESSION OF CD4+CD25+TREG IN PERIPHERAL BLOOD OF RECURRENT IMPLANTATION FAILURE**  
**L. Hua, China**
- 17:30-17:40 **INTRA UTERINE INSEMINATION- WHEN, WHERE AND HOW?**  
**S. Das, India**
- 17:40-17:50 **A NEW GENOTYPING METHOD FOR DETECTING LOW ABUNDANCE SINGLE NUCLEOTIDE MUTATIONS BASED ON GAP LIGASE CHAIN REACTION AND QUANTITATIVE PCR ASSAY**  
**P. Yi, China**



# SATURDAY, DECEMBER 10, 2011

## Infertility and ART

HALL A

08:30-10:00	<b>ASSESSMENT AND TREATMENT OF OVARIAN RESERVE</b>
Capsule	<i>Diminished ovarian reserve (DOR) remains a common, frustrating and Under diagnosed condition. Lack of criteria for diagnosis makes it difficult to assess and compare prevalence of diagnosis and results of treatments. Questions have been raised as to whether DOR even lends itself to treatment and, if so, whether treatment regimen results differ</i>
Chairpersons	<b>C. De Geyter</b> , Switzerland <b>M. Benkhalifa</b> , France <b>S.A. Carson</b> , USA
08:30-08:55	Has Anti-Müllerian Hormone (AMH) Become Essential in Assessing Ovarian Reserve? <b>S. Daya</b> , Canada
08:55-09:40	Debate <b>Can Diminished Ovarian Reserve be Treated Effectively?</b> <b>Yes: N. Gleicher</b> , USA <b>No: S. Daya</b> , Canada Discussion
09:40-10:00	2000 IU of hCG in responders does not affect the outcome of IVF <b>Y. Kuang</b> , China
Objectives	<i>Upon completion of these debates, the audience will have learned the following:</i> <ul style="list-style-type: none"><li>• How DOR is defined in the literature</li><li>• Why age-specific ovarian reserve determination improves sensitivity of diagnosis of DOR</li><li>• What the best methodologies are for diagnosing DOR</li><li>• Whether DOR lends itself to treatment</li></ul>
10:00-10:20	<b>Coffee break</b>
10:20-11:50	<b>POLYCYSTIC OVARIAN SYNDROME (PCOS) AND OHSS</b>
Capsule	<i>Controversy over the management of <b>Polycystic Ovarian Syndrome</b> (PCOS) patients continues. These patients tend to have ovarian hyperstimulation syndrome (OHSS) and multiple pregnancies when stimulated. The debate here is what should be the first step of treatment? Should we start with stimulation +IUI which can't prevent multiples or should we just proceed with IVF?</i>
Chairpersons	<b>E. Manalo</b> , Philippines <b>S. Daya</b> , Canada <b>H.F. Huang</b> , China
10:20-11:05	Debate <b>Treating Anovulatory PCOS Patients: What Should be the First Choice?</b> Gonadotropins versus clomiphene citrate as first line therapy to improve pregnancy rate <b>S. Daya</b> , Canada Ovulation induction +IUI and/or IVF <b>N. Gleicher</b> , USA Discussion
11:05-11:30	PCOS in Filipino women <b>E. Manalo</b> , Philippines
11:30-11:50	Do PCOS patients have delayed ovarian aging? <b>Z. Ben Rafael</b> , Israel
Objectives	<i>To acquire knowledge about the following:</i> <ul style="list-style-type: none"><li>• The most effective primary treatment for PCOS</li><li>• Advantages and limitations of treatment options</li></ul>
11:50-12:10	<b>Poster viewing</b>

**12:10-13:40 HOT CONTROVERSIES ON ART CLINICAL ISSUES**

Moderators  
**Z. Ben Rafael**, Israel  
**C.Q. Zhou**, China

Discussants  
**Z.J. Chen**, China  
**S. Daya**, Canada  
**N. Gleicher**, USA  
**S.A. Carson**, USA  
**M. Benkhalifa**, France

**Round Table Discussion and Expert Opinions on:**

1. Should tests of ovarian reserve be routinely done
2. Low dose or high dose: Which are the preferred responders
3. Protocols for IVF in patients with endometriosis
4. Strategies to prevent OHSS
5. Cheaper IVF: How can it be achieved?
6. Alternative medicine for IVF: Is it over-rated? Merely a placebo effect?
7. Difficult ET, what is the next step?
8. Assisted zona hatching: Should it be continued?
9. Luteal support in IVF: PO? PV? IM? For how long?
10. Should PGD be routine in patients with recurrent miscarriages?

**13:40-14:30 Lunch break**

**14:30-16:00 BASIC ASPECTS OF ART**

Chairpersons  
**X.C. Yu**, China  
**J. Zhang**, China  
**S.A. Carson**, USA

14:30-14:55 Multipotent adult germ line stem cells: New therapeutic hope?  
**R. Schwartz**, USA

14:55-15:15 Genetic imprinting and embryonic development  
**H.F. Huang**, China

15:15-15:40 The value of sperm morphology  
**Z.W. Chen**, China

15:40-16:00 Embryonic stem cell therapeutic potential: Is the future here?  
**Y.L. Ma**, China

**16:00-16:30 Coffee break**

**16:30-18:00 ONCOFERTILITY: THE PRESERVATION OF FUTURE GENERATIONS**

Capsule  
*About 75% of children treated for cancer are expected to be long term survivors, and hence fertility preservation is one of the aims of the treatment that also allows for normal life experience. The multiple modalities of treatment which include modified surgery, alternative modalities of chemotherapies, can help preserve fertility. Newer techniques, even if still experimental like gamete freezing, in vitro maturation (IVM) and IVF, expand the choices. Fertility saving surgery can be performed in certain cancer cases, however no clear guidelines or limits are set, and the age in which these procedures should be offered is controversial*

Chairpersons  
**Z.J. Chen**, China  
**M. von Wolff**, Switzerland  
**O. Coll**, Spain

16:30-17:00 Should fertility be saved in the infants and adolescents with malignancies?  
**S.A. Carson**, USA

17:00-17:30 Should fertility be spared in women with ovarian malignancies?  
**S. Granai**, USA

17:30-18:00 Prophylactic surgery in BRCA gene patients: What should be done and when?  
**R. Moore**, USA

08:30-10:00

**COSMETIC GENITAL SURGERY**

Capsule

*The reasons for the current surge in popularity of cosmetic genital surgery are not completely understood. Are they related to the surge in availability? To new methods and technologies that were introduced, to a real need or to a good marketing strategy? What are the methods, who are the patients, what are the perils and who should provide the services?*

Chairperson

**A. Ostrzenski**, USA

08:30-09:00

Deceptive and unethical procedures in cosmetic-plastic gynecology: Difficulties in identifying and eliminating them from the practice

**T. Hailparn**, USA

09:00-09:30

Progress in cosmetic-plastic gynecology: New surgical interventions combine gynecologic and general cosmetic-plastic operations, and natural or synthetic fillers

**M.N. Scheinberg**, USA

09:30-10:00

Cosmetic-plastic gynecology: Complications and how to avoid them

**A. Ostrzenski**, USA

Objectives

*Anything you wanted to ask about Cosmetic genital surgery and never dared to ask.....*

10:00-10:20

**Coffee break**

10:20-11:50

**CONTROVERSIES IN THE TREATMENT OF MALIGNANCIES**

Capsule

*Are there new aggressive procedures coupled with better survival rates? Expert opinion on a variety of clinical dilemmas in oncology*

Chairperson

**C.O. Granai**, USA

Discussants

**R. Moore**, USA**T. Levy**, Israel**T.H. Cheung**, Hong Kong**S. Wilailak**, Thailand**Surgery**

- Oophorectomy at hysterectomy: Is there a cut off age?
- Should Low Malignant Potential tumors be surgically staged?
- Lymphadenectomy for early stage endometrial cancer?
- Lymphadenectomy for ovarian CA: Is it really necessary?
- Aggressive cytoreductive surgery should be the first step in the management of ovarian cancer?
- Surgery or primary chemo-radiation for stage 1B2 cervical cancer?

**Therapy**

- Adjuvant chemotherapy for ovarian malignant tumors of low potential
- Neo-adjuvant chemotherapy for advanced-stage ovarian cancer and cervical cancer
- Platinum-sensitive relapse ovarian CA outcome and quality of life?
- Intraperitoneal chemotherapy in ovarian cancer

11:50-12:10

**Poster viewing**

<b>12:10-13:40</b>	<b>ENDOSCOPY</b> <i>Supported by unrestricted grant from Karl Storz GMBA</i>
Capsule	<i>Should we continue to expand on indications for endoscopy?</i>
Chairpersons	<b>T. Levy</b> , Israel <b>R. Campo</b> , Belgium
12:10-12:40	Trophy's choice? New generation of Hysteroscope <b>R. Campo</b> , Belgium
12:40-13:10	Endometriosis of bowel, bladder, ureter, diaphragm, lumps and liver <b>CR. Nezhath</b> , USA
13:10-13:40	A new approach to the diagnosis of adenomyosis "Hysteroscopic exploration of the sub endometrial myometrium" <b>R. Campo</b> , Belgium
Objectives	<i>To acquire knowledge of the following:</i> <ul style="list-style-type: none"> <li>• <i>Surgical treatment of endometriosis</i></li> <li>• <i>Introduction to Trophy's choice</i></li> <li>• <i>The place of hysteroscopy in the management of infertility</i></li> <li>• <i>Diagnosis of adenomyosis</i></li> </ul>
<b>13:40-14:30</b>	<b>Lunch break</b>
<b>14:30-16:00</b>	<b>OPERATIVE PROCEDURES: TRICKS OF THE TRADE</b>
Capsule	<i>Results of surgery depend on choosing the right procedure for the right patient, and recognizing the pitfalls and risks of the operation. Good results also depend on a meticulous technique. How can all these be improved?</i>
Chairpersons	<b>R. Campo</b> , Belgium <b>C.R. Nezhath</b> , USA
14:30-14:55	Pain, infertility, pregnancy and endometriosis: Ancient conditions, ancient correlations and their ancient treatment <b>C.R. Nezhath</b> , USA
14:55-15:15	Cosmetic-Plastic Gynecology: Controversy and progress <b>A. Ostrzenski</b> , USA
15:15-15:40	Intra uterine adhesions (IUA) "Prevention and Treatment" a major challenge <b>R. Campo</b> , Belgium
15:40-16:00	Mesh vs. non-mesh reconstruction for urinary incontinence <b>D. Dodero</b> , Italy
Objectives	<i>Upon completion of this session, the audience will learn:</i> <ul style="list-style-type: none"> <li>• <i>Where we are in containing endometriosis pain?</i></li> <li>• <i>The new surge in popularity of cosmetic genital surgery</i></li> <li>• <i>Withstanding the challenge of IUA</i></li> <li>• <i>To mesh or not to mesh, this is the question!</i></li> </ul>
<b>16:00-16:30</b>	<b>Coffee break</b>
<b>16:30-18:00</b>	<b>CERVICAL CANCER AND HUMAN PAPILLOMA VIRUS (HPV)</b>
Capsule	<i>Does vaccination mark the end of cervical cancer?</i>
Chairpersons	<b>C.P. Zou</b> , China

Discussants  
**R. Moore**, USA  
**T. Levy**, Israel  
**S. Wilailak**, Thailand  
**T.H. Cheung**, Hong Kong

**Hot Controversies – Expert Opinions on:**

1. The difference between quadrivalent or bivalent HPV vaccine
2. The efficacy of vaccination in adolescents and women over 30 years of age
3. For how long does immunization provide immunity? Booster after 10 years?
4. Whether current knowledge implies immunization against cancer, or merely precancerous stages?
5. Is there concern that migration to other types of HPV will become the main cause of HPV-related cervical cancer?
6. Should males be vaccinated?
7. Is the Pap smear obsolete in immunized patients?
8. Do we still need HPV-DNA typing?
9. Routine inclusion of colposcopy in a pelvic examination. If so, how often?

## Fetomaternal Medicine

HALL C

<b>08:30-09:00</b>	<b>COMPLICATIONS OF PREGNANCY AND DELIVERY</b>
Capsule	<i>Life-threatening situations in obstetrics should be identified and treated early</i>
Chairpersons	<b>W.H. Tam</b> , Hong Kong <b>I. Blickstein</b> , Israel
08:30-09:00	New insights into the pathophysiology of preeclampsia: Consequences for prediction and prevention <b>W. Holzgreve</b> , Switzerland
09:00-09:30	What is the best maneuver to relieve shoulder dystocia and safety limit for head-to-body delivery interval? <b>T.Y. Leung</b> , Hong Kong
09:30-10:00	Stem cells from cord blood and other sources: What the obstetricians/ gynecologists should know? <b>W. Holzgreve</b> , Switzerland
Objectives	<i>Upon completion of this session, the audience will have learned:</i> <ul style="list-style-type: none"> <li>• <i>Managing Shoulder dystocia</i></li> <li>• <i>Prevention of complications by better prediction</i></li> <li>• <i>What to do with cord blood?</i></li> </ul>
<b>10:00-10:20</b>	<b>Coffee break</b>
<b>10:20-11:50</b>	<b>CERCLAGE</b>
Capsule	<i>Cerclage is being used in increasing frequency despite the lack of RCT</i>
Chairpersons	<b>T.Y. Leung</b> , Hong Kong <b>H. Divakar</b> , India
10:20-11:05	<p>Debate</p> <p><b>Does Cervical Cerclage with Bulging Membranes Extend Pregnancy Beyond Conservative Treatment? What is the Evidence?</b></p> <p><b>No Evidence:</b> Conservative treatment will achieve similar results. The risk of infection is too high to keep experimenting</p> <p><b>I. Blickstein</b>, Israel</p> <p>Selection of patients and meticulous technique is the key to success in emergency cerclage</p> <p><b>W.H. Tam</b>, Hong Kong</p> <p>Discussion</p>
11:05-11:30	The role of “repeated dose” steroids <b>T.Y. Leung</b> , Hong Kong
11:30-11:50	Progesterone treatment for PTL <b>S. Luming</b> , China
Objectives	<i>Upon completion of this session, the audience will have learned:</i> <ul style="list-style-type: none"> <li>• <i>The place of late cerclage in the management of bulging membranes</i></li> <li>• <i>Technique, indication, and contraindication of late cerclage</i></li> <li>• <i>Use of corticosteroids</i></li> </ul>



11:50-12:10	<b>Poster viewing</b>
<b>12:10-13:40</b>	<b>MULTIPLE PREGNANCIES</b>
Capsule	<i>The modern epidemic of multiple pregnancies might have many reasons but has one profound effect on perinatal results. Recognizing the risk might be the first step for prevention</i>
Chairpersons	<b>M. Robson</b> , Ireland <b>W.H. Tam</b> , Hong Kong
12:10-12:40	How do iatrogenic multiple pregnancies complicate perinatal care? <b>I. Blickstein</b> , Israel
12:40-13:10	FetoscopicLaser treatment of twin to twin transfusion syndrome: More than "see and burn" <b>T.Y. Leung</b> , Hong Kong
13:10-13:40	Selective IUGR in twins <b>S. Luming</b> , China
Objectives	<i>Upon completion of this session, the audience will have learned:</i> <ul style="list-style-type: none"> <li>• <i>Risks and complications of multiple pregnancies</i></li> <li>• <i>Treating TTS</i></li> <li>• <i>IUGR in twins</i></li> </ul>
<b>13:40-14:30</b>	<b>Lunch break</b>
<b>14:30-16:00</b>	<b>HIGH RISK PREGNANCIES IN ART: A PRICE TO PAY</b> (Bilateral encounter of Primatologists and Infertility Specialists)
Capsule	<i>It seems as if there are two monologues going on simultaneously. ART- specialists are opting for the highest pregnancy rates defying the limitations on reproduction set by nature on male and female fertility. On the other hand, age, female chronic diseases, multiple pregnancies, and parental genetic deficiencies have opened a whole new field of "ART high risk pregnancies" opting to secure the safest delivery and perinatal outcome in these extreme situations. Conversely, an open dialogue, which will allow the perinatologists to influence the "point of entry" to ART treatments, might result in higher barriers on personal rights to peruse their plans. What kind of dialogue should we develop?</i>
Chairpersons	<b>Z. Ben-Rafael</b> , Israel <b>H. Divakar</b> , India
14:30-15:00	Medical complications of pregnancy resulting from IVF: What do we know and what don't we know? <b>I. Blickstein</b> , Israel
15:00-16:00	<p>Debate</p> <p><b>Preconception Counseling for ART: Who Should Inform the Women About the Risks?</b></p> <p><b>Proposition:</b> Patients are ready to take the many risk in their journey to parenthoods, and ART specialists are fully trained, to weigh the risk/benefit in most situations, hence they should be the primary physicians to provide counseling <b>N. Gleicher</b>, USA</p> <p><b>Opposition:</b> ART specialists might be in conflict when counseling women on the plethora of perinatal risks that they might face. <b>I. Blickstein</b>, Israel</p> <p>Discussion: What kind of dialogue should we develop?</p>
Objectives	<i>Upon completion of this session, the audience will have learned:</i> <ul style="list-style-type: none"> <li>• <i>The plethora of risks involved in ART pregnancies</i></li> <li>• <i>The conflicts facing the preconception counselor</i></li> <li>• <i>The mounting price of multiple pregnancies</i></li> </ul>
<b>16:00-16:30</b>	<b>Coffee break</b>
<b>16:30-18:00</b>	<b>COMPLICATIONS OF PREGNANCY (II)</b>
Chairpersons	<b>T.Y. Leung</b> , Hong Kong <b>H. Divakar</b> , India
16:30-17:00	New drugs to reduce post-partum hemorrhage <b>I. Blickstein</b> , Israel
17:00-17:30	Reducing maternal anemia in the 3 <sup>rd</sup> world <b>H. Divakar</b> , India

17:30-18:00 Myomectomy during CS  
**Z. Ben-Rafael**, Israel

Objectives *Upon completion of this session, the audience will have learned:*

- Controlling PPH
- Controlling Anemia during pregnancy
- Myomectomy: To whom by whom?

## Oral Presentations

Hall D

### 08:30-10:00 ORAL SESSION 5: INFERTILITY

Chairperson **E. Manalo**, Philippines

08:30-08:40 **SUCCESSFUL PREGNANCY AFTER TESE-ICSI IN NON MOSAIC KLINEFERTER SYNDROME**  
**M. Fasolino**, L. Gianaroli, T. Notari, N. Grieco, M. Maiello, *Italy*

08:40-08:50 **LAPAROSCOPIC EVALUATION OF FEMALE FACTORS IN INFERTILITY**  
**N. Aziz**, *Pakistan*

08:50-09:00 **ABNORMAL EXPRESSION OF TIM-3 IN UNEXPLAINED RECURRENT SPONTANEOUS ABORTION**  
**M. Zhang**, Z. Yuanzhen, *China*

09:00-09:10 **THE VERY EARLY PREGNANCY**  
**Z. Linghao**, *China*

09:10-09:20 **IMPORTANCE OF LH-HARMON**  
**R. Tyagi**, *India*

09:20-09:30 **THE APPLICATION OF MINI-STIMULATION PROTOCOL WITH GNRH-A IN IVF FOR POOR RESPONDERS**  
**S. Lijun**, *China*

09:30-09:40 **VITRIFIED-WARMED BLASTOCYST TRANSFER CYCLES YIELD HIGHER PREGNANCY AND IMPLANTATION RATES COMPARED WITH FRESH BLASTOCYST TRANSFER CYCLES: TIME FOR A NEW EMBRYO TRANSFER STRATEGY?**  
**G. Tong**, *China*

09:40-09:50 **LAPAROSCOPIC STRASSMAN METROPLASTY FOR BICORNUATE UTERUS WITH SUCCESSFUL PREGNANCY OUTCOME**  
**H. Asefjah**, *Islamic Republic of Iran*

09:50-10:00 **COMPARATIVE STUDY BETWEEN DIFFERENT PROTOCOLS OF INTRAUTERINE INSEMINATION FOR WOMEN WITH UNEXPLAINED INFERTILITY**  
**A. Maged**, *Egypt*

### 10:20-11:50 ORAL SESSION 6: FETOMATERNAL MEDICINE

Chairperson **M. Robson**, Ireland

10:20-10:30 **EXTIRPATIVE VERSUS CONSERVATIVE MANAGEMENT OF PLACENTA ACCRETA: A PROVINCIAL HOSPITAL EXPERIENCE**  
**R. Arigue**, A. Teotico, *Philippines*

10:30-10:40 **CLINICAL ANALYSES OF 24 CASES OF LAPAROSCOPIC SURGERY FOR ADNEXAL MASSES IN SECOND TRIMESTER**  
**P. Peng**, *China*

10:40-10:50 **FETOSCOPIC LASER ABLATION FOR THE TREATMENT OF TWIN TO TWIN TRANSFUSION SYNDROME: THE EGYPTIAN EXPERIENCE**  
**M. Momtaz**, *Egypt*

10:50-11:00 **EARLY CORD CLAMPING AND DELAYED CORD CLAMPING ON MATERNAL AND NEONATAL OUTCOMES**  
**H. Zhang**, *China*

11:00-11:10 **THE ALTERNATION OF REGULATORY T CELLS AND B CELL-SUBSETS IN PERIPHERAL BLOOD: IS THE IMBALANCE OF THESE CELLS INVOLVED IN THE PATHOGENESIS OF PREECLAMPSIA?**  
**B. Zeng**, Y. Zhang, X. Zhang, A. Liao, *China*

11:10-11:20 **TRENDS IN ECTOPIC PREGNANCY MORTALITY IN SHANGHAI, CHINA: 1979-2010**  
**L. Du**, L. Zhu, *China*

11:20-11:30 **PREVALENCE, OBSTETRIC RISK FACTORS AND NATURAL HISTORY OF ASYMPTOMATIC POSTPARTUM URINARY RETENTION AFTER FIRST VAGINAL DELIVERY- A PROSPECTIVE STUDY OF 200 PRIMIPARA WOMEN**  
**Y. Salemnick**, D. Gordon, J.B. Lessing, R. Gold, M. Kupferminc, O. Groutz, *Israel*

11:30-11:40 **COMPARATIVE STUDY BETWEEN CONTINUOUS USE OF OXYTOCIN INFUSION THROUGHOUT THE ACTIVE PHASE OF LABOR VERSUS ITS DISCONTINUATION**  
**A. Maged**, **A. Rashwan**, H. Gaffar, *Egypt*

11:40-11:50 **PROGESTIN TREATMENT FOR THE PREVENTION OF PRETERM BIRTH**  
**L. Shi**, S-Q. Shi, R.E. Garfield, *USA*

**12:10-13:40 ORAL SESSION 7: FETOMATERNAL MEDICINE/GYNECOLOGY**

- Chairperson **T. Levy, Israel**
- 12:10-12:20 **A PROMISING CONSERVATIVE TREATMENT OPTION FOR CERVICAL PREGNANCY: ANGIOGRAPHIC UTERINE ARTERY EMBOLIZATION FOLLOWED BY IMMEDIATE CURETTAGE**  
**B. Xu, Y. Wang, Y. Duan, Y. Ma, N. Jiang, C. Sun, China**
- 12:20-12:30 **SURVEY ABOUT FERROUS ANEMIA IN PREGNANT WOMEN WHO HAD GONE TO SHIRAZ MEDICAL CENTERS FOR CHECKUP IN 2009**  
**N. Sharifi, Islamic Republic of Iran**
- 12:30-12:40 **SURGICAL MENOPAUSE AND HORMONAL REPLACEMENT THERAPY**  
**V. Mahasani, India**
- 12:40-12:50 **INVESTIGATING THE ENHANCEMENT OF COMBINATION OF CARBOPLATIN AND PAKLITAKSEL WITH ATRA TREATMENT ON OVCAR-3 CELLS**  
**C. Yildiz Eren, S. Ozalp, A. Koparal, R. Bostancioglu, Turkey**
- 12:50-13:00 **COMPARISON OF DIFFERENT TECHNIQUES OF SENTINEL LYMPHATIC MAPPING IN ENDOMETRIAL CANCER**  
**M. Halaska, H. Robova, M. Pluta, L. Rob, Czech Republic**
- 13:00-13:10 **FETAL MICROCHIMERISM IN ENDOMETRIAL CANCER**  
**I. Hromadnikova, K. Kotlabova, Z. Vernerova, B. Svoboda, P. Libalova, Czech Republic**
- 13:10-13:20 **EXPRESSIONS OF CXCL12 /CXCR4 AND CXCL16 /CXCR6 AXES BY CIN AND CERVICAL CANCER**  
**Y. Huang, Z. Cui, China**
- 13:20-13:30 **CONSERVATIVE TREATMENT OF OVARIAN CANCER SAFETY, OVARIAN FUNCTION PRESERVATION, REPRODUCTIVE ABILITY, AND EMOTIONAL ATTITUDE OF THE PATIENTS IN SAUDI ARABIA**  
**A. Almrstani, K. Sait, Saudi Arabia**
- 13:30-13:40 **A STUDY OF NATURAL HISTORY OF HPV IN CERVICAL TUMORS: IDENTIFICATION OF GENOTYPES FROM FORMALIN FIXED CERVICAL TISSUES**  
**M.H. Bukhari, K. Saba, M. Zainab, G. Ahmad, A. Siddiq, I. Qaderi, M. Anwar, Pakistan**

**14:30-16:00 ORAL SESSION 8: FETOMATERNAL MEDICINE/GYNECOLOGY**

- Chairperson **A. Mueck, Germany**
- 14:30-14:40 **HAEMOSTASIS IN ENDOSCOPY –THE BEST TECHNIQUE**  
**K. Das, India**
- 14:40-14:50 **LAPAROSCOPIC VERSUS ABDOMINAL MYOMECTOMY: A PROSPECTIVE, RANDOMIZED TRIAL TO EVALUATE BENEFITS IN EARLY OUTCOME**  
**M. Walaa Eldeeb, A. Hazem, H. Yousef, M. Abushaeer, Egypt**
- 14:50-15:00 **BEDSIDE ULTRASOUND CAN SUCCESSFULLY PREDICT NEED FOR OPERATIVE INTERVENTION IN SUSPECTED ECTOPIC PREGNANCY**  
**A. Anwer, Pakistan**
- 15:00-15:10 **LAPAROSCOPIC VERSUS ABDOMINAL MYOMECTOMY: A PROSPECTIVE, RANDOMIZED TRIAL TO EVALUATE BENEFITS IN EARLY OUTCOME**  
**M. Eldeeb, Egypt**
- 15:10-15:20 **THREE POINTS OF RELIABLE ANCHOR OF THE MESH IN POP SURGERY**  
**L. Salimova, O. Shalae, V. Radzinsky, T. Ignatenko, F. Eseneeva, E. Ordiyantc, S. Parsadanyan, R. Omarova, Russian Federation**
- 15:20-15:30 **CYCLIC CHANGES AND RELATIONSHIP OF PERIPHERAL AND ENDOMETRIAL NK CELLS DURING MENSTRUAL CYCLE**  
**Y. Zhang, B. Zeng, X. Zhang, A. Liao, China**
- 15:30-15:40 **EFFECT OF AROMATHERAPY MASSAGE ON MENOPAUSAL SYMPTOMS USING MENOPAUSAL RATING SCALE**  
**F. Darsareh, S. Taavoni, Islamic Republic of Iran**
- 15:40-15:50 **THE EFFECTIVENESS OF ENDOMETRIAL THICKNESS ON TRANSVAGINAL SCAN IN PATIENTS WITH PREMENOPAUSAL DYSFUNCTIONAL UTERINE BLEEDING TO DETECT ENDOMETRIAL HYPERPLASIA**  
**G. Agarwal, India**
- 15:50-16:00 **MEMBRANE-INITIATED PROGESTOGEN EFFECTS ON THE PROLIFERATION OF HUMAN BREAST CANCER CELLS ARE DEPENDENT ON THE KIND OF PROGESTOGEN USED**  
**X. Ruan, H. Neubauer, H. Seeger, R. Chen, Q. Yu, A. Mueck, China and Germany**

# SUNDAY, DECEMBER 11, 2011

## Infertility and ART

HALL A

08:30-10:00

### RESCUE ICSI, SHOULD WE KEEP DOING IT?

Capsule

*Is rescue ICSI as effective if fertilization fails after conventional IVF? In this controversial question it is only certain that we need to do it early enough within the "rescue window" before oocyte aging, but how early?*

Chairpersons

**C. Zhou**, China  
**G. Huang**, China  
**S. Daya**, Canada

08:30-09:25

Debate

### Is Early application of rescue ICSI (3-8 hours after insemination) effective in conventional IVF?

**Yes:** provided that it is done early enough before oocytes aging it can be used often

**H. Sun**, China

**No:** It should be used restrictively

**Y. Huang**, China

**Yes again!** It should be performed with reservation

**G. Huang**, China

09:25-10:00

Debate

### Luteal phase support? Is it really needed?

**Proposition:** There is no clear evidence show luteal phase support is necessary in routing ART

**G. Zhu**, China

**Opposition:** Luteal phase support is important in IVF

**C. Zhou**, China

Discussion

10:00-10:20

Coffee break

10:20-11:50

### ENDOMETRIOSIS: WHAT IS THE BEST TREATMENT FOR INFERTILE PATIENTS?

Capsule

*Can we choose from the many therapeutic options available for this poorly understood condition?*

Chairpersons

**Y.H. Huang**, China  
**M. Benkhalifa**, France  
**Y. Huang**, China

10:20-11:05

Debate

### Endometriosis – surgery or IVF?

IVF first: **J. Lang**, China

Surgery first: **G.A. Chen**, China

Discussion

11:05-11:30

Role of laparoscopic treatment of endometriosis in patients with failed IVF

**Y.Q. Yao**, China

11:30-11:50

What should be done with recurrent endometriosis in infertile patients?

**S.H. Yao**, China

## Gynecology

## HALL A

08:30-10:00

### HORMONE THERAPY (HT) AND CANCER RISK

Capsule

*The fear of cancer still dominates the decisions of physicians and patients regarding initiation and continuation of HT*

Chairpersons

**S. Skouby**, Denmark

**E. Peer**, Israel

08:30-09:30

#### Debate

**Proposition:** Breast cancer risk is related to the recommended HT dose and regimen!

**A. Mueck**, Germany

**Opposition:** It is impossible to predict women in whom HT will not increase the risk for breast cancer, and in any event it is unrelated to the dose and regimen!

**R. Langer**, USA

Discussion

09:30-10:00

Breast cancer risk and hormone replacement therapy: Is the choice of the progestogens important?

**X. Ruan**, China

Objectives

*Upon completion of this session, the audience will acquire knowledge:*

- *What risks are associated with progesterone?*
- *Risk and prevention of HT associated breast cancer*

10:00-10:20

**Coffee Break**

10:20-11:50

**SPECIAL SESSION OF THE RUSSIAN SOCIETY OF OB/GYN IN CONJUNCTION WITH COGI CHINA**

**TBA**

